<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="524">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04435184</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00249874</org_study_id>
    <nct_id>NCT04435184</nct_id>
  </id_info>
  <brief_title>Crizanlizumab for Treating COVID-19 Vasculopathy</brief_title>
  <acronym>CRITICAL</acronym>
  <official_title>Crizanlizumab for Treating COVID-19 Vasculopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Socar Research SA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to test the efficacy and safety of crizanlizumab in patients
      hospitalized with COVID-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infection with severe acute respiratory syndrome (SARS) coronavirus 2 (CoV-2) causes
      coronavirus disease 2019 (COVID-19). The clinical course of COVID-19 is variable, and some
      patients develop severe pneumonia, multi-organ failure, and shock.

      Severe COVID-19 is characterized by a hyper-inflammatory and hyper-thrombotic state. We
      propose that this state is caused by viral injury of the vascular endothelium, leading to
      endothelial release of von Willebrand Factor (VWF) and P-selectin, which in turn drive
      thrombosis and vascular inflammation.

      Crizanlizumab is a monoclonal antibody that targets P-selectin. Crizanlizumab can decrease
      inflammation by binding to P-selectin, blocking leucocyte and platelet adherence to the
      vessel wall.

      We now plan to test the safety and efficacy of crizanlizumab in decreasing biomarkers of
      inflammation and thrombosis in a placebo-controlled, double-blind randomized clinical trial
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind, placebo-controlled, randomized interventional trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Soluble P-selectin level</measure>
    <time_frame>Day 3 after randomization or day of hospital discharge, whichever is earlier</time_frame>
    <description>Level of soluble P-selectin in ng/ml.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Soluble P-selectin level</measure>
    <time_frame>Day 7 after randomization</time_frame>
    <description>Level of soluble P-selectin in ng/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble P-selectin level</measure>
    <time_frame>Day 14 after randomization</time_frame>
    <description>Level of soluble P-selectin in ng/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer level</measure>
    <time_frame>Day 7 after randomization</time_frame>
    <description>Level of D-dimer in mg/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer level</measure>
    <time_frame>Day 14 after randomization</time_frame>
    <description>Level of D-dimer in mg/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VWF level</measure>
    <time_frame>Day 7 after randomization</time_frame>
    <description>Level of VWF antigen (percentage).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VWF level</measure>
    <time_frame>Day 14 after randomization</time_frame>
    <description>Level of VWF antigen in (percentage).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP level</measure>
    <time_frame>Day 7 after randomization</time_frame>
    <description>Level of C-reactive protein (CRP) in mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP level</measure>
    <time_frame>Day 14 after randomization</time_frame>
    <description>Level of C-reactive protein (CRP) in mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical status as assessed by the World Health Organization (WHO) Ordinal Scale for COVID-19 Trials</measure>
    <time_frame>Daily up to day 14 after randomization</time_frame>
    <description>Change in the clinical status over 14 days as measured by an ordinal scale that is the first assessment of the clinical status on a given study day. The scale is as follows:
0 = Uninfected; no viral RNA detected
= Ambulatory; asymptomatic; viral RNA detected
= Ambulatory; symptomatic; independent
= Ambulatory; symptomatic; assistance needed
= Hospitalized; no oxygen therapy
= Hospitalized; oxygen by mask or nasal prongs
= Hospitalized; oxygen by non-invasive ventilation (NIV) or high flow
= Hospitalized; intubation and mechanical ventilation, partial pressure of oxygen / fraction of inspired oxygen (pO2/FIO2) ≥ 150 or oxygen saturation / FIO2 (SpO2/FIO2) ≥ 200
= Hospitalized; intubation and mechanical ventilation, pO2/FIO2 &lt; 150 or SpO2/FIO2 &lt; 200 or vasopressors
= Hospitalized; intubation and mechanical ventilation, pO2/FIO2 &lt; 150 or SpO2/FIO2 &lt; 200 and vasopressors, dialysis, or extracorporeal membrane oxygenation (ECMO)
= Dead</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hospital discharge</measure>
    <time_frame>Up to 30 days after randomization</time_frame>
    <description>Time (days) to hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Crizanlizumab as assessed by adverse events</measure>
    <time_frame>Up to day 14 after randomization</time_frame>
    <description>Safety of crizanlizumab will by assessed by adverse events, serious adverse events, and suspected unexpected serious adverse reactions.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Crizanlizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crizanlizumab is a monoclonal antibody targeting P-selectin. Crizanlizumab 5.0 mg/kg in 100 ml IV once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.9% saline 100 ml IV once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizanlizumab</intervention_name>
    <description>Crizanlizumab 5.0 mg/kg in 100 ml IV once.</description>
    <arm_group_label>Crizanlizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>0.9% saline</intervention_name>
    <description>0.9% saline 100 ml IV once.</description>
    <arm_group_label>Placebo Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing to provide written informed consent

          2. Willing to comply with all study procedures and be available for the duration of the
             study

          3. Male or female ≥ 18 years of age

          4. SARS-CoV-2 infection (COVID-19) within the past 10 d documented by laboratory test
             (nucleic acid test (NAT) or reverse transcriptase-polymerase chain reaction (RT-PCR))

          5. Currently hospitalized

          6. Symptoms of acute respiratory infection (at least one of the following: cough, fever &gt;
             37.5°C, dyspnea, sore throat, anosmia),

          7. Radiographic evidence of pulmonary infiltrates

          8. Requiring supplemental oxygen or the peripheral capillary oxygenation saturation
             (SpO2) &lt; 94% on room air at screening

          9. Elevated D-Dimer &gt; 0.49 mg/L

         10. Negative pregnancy test for females of childbearing potential

        Exclusion Criteria:

          1. Use of home oxygen at baseline

          2. Current use of mechanical ventilation

          3. Inability to provide consent

          4. Do not intubate status

          5. Prisoner or incarcerated

          6. Pregnancy or Breast Feeding

          7. Participation in other interventional therapy trials for COVID-19.

          8. International normalized ratio (INR) &gt; 3 or activated partial thromboplastin time
             (aPTT) &gt; 60
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles J Lowenstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles Lowenstein, MD</last_name>
    <phone>(410) 955-3097</phone>
    <email>clowens1@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thorsten Leucker, MD PhD</last_name>
    <phone>‭(410) 502-9453‬</phone>
    <email>tleucke1@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles J Lowenstein, MD</last_name>
      <phone>410-955-3097</phone>
      <email>clowens1@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Shannon Kelley, BS</last_name>
      <phone>‭(410) 688-9934‬</phone>
      <email>skelle31@jhu.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW, Rother RP. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med. 2017 Feb 2;376(5):429-439. doi: 10.1056/NEJMoa1611770. Epub 2016 Dec 3.</citation>
    <PMID>27959701</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 16, 2020</study_first_submitted>
  <study_first_submitted_qc>June 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2020</study_first_posted>
  <last_update_submitted>September 22, 2020</last_update_submitted>
  <last_update_submitted_qc>September 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>coronavirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

